Patients with a history of uncontrolled seizure disorder; including focal or generalized seizure may not have had a seizure within one year prior to registration
Seizure disorders requiring anticonvulsant therapy.
Documented history of or current brain metastases due to seizure risk
Contraindication to the use of bupropion including seizure disorder or conditions that increase the risk of seizure (including bulimia and/or anorexia nervosa, central nervous system [CNS] tumor, severe stroke, abrupt withdrawal from benzodiazepines or alcohol)
Known brain metastases or history of seizure
Patients with active seizure or history of seizure are not eligible
Have a history of a seizure
Seizure disorders requiring anticonvulsant therapy.
Past or current history of epilepsy or seizure disorder; exception: well-documented febrile seizure of childhood
Known central nervous system (CNS) metastases or seizure disorder; patients with known brain metastases that have been successfully treated and stable for >= 6 months without requirement for corticosteroids and without seizure activity will be eligible
Inadequate seizure control
Patients with active seizure or a history of seizure are not eligible
Patients must NOT have active seizure(s) or history of seizure(s)
PHASE II: Patients must NOT have active seizure(s) or history of seizure(s)
Patients with a history of seizure disorder requiring antiepileptics who have had a seizure episode within the last 6 months
Patients with history of seizure disorder requiring antiepileptics who have had a seizure episode within the last 6 months
For Cohort C: Has a history of seizure or any condition that may predispose to seizure
Patients must not have active seizure or history of seizure
Subject has a history of seizure or any condition that may predispose to seizure.
History of seizure or any condition that may predispose to seizure;
A history of seizure within 12 months prior to study entry.
Has a history of seizure
History of seizure or any condition or concurrent medication that may predispose to seizure
Concurrent therapy with medications known to have seizure potential
History of seizure or any condition or concurrent medication that may predispose to seizure
past history of seizure due to any cause except a single febrile seizure in childhood. Patients with a history of seizures should not have had a seizure within 12 months of Screening and must have had no anticonvulsants for 12 months prior to Screening,
Subject has a history of seizure within the past 12 months of Screening as assessed by neurology examination and history.
History of seizure or condition that may pre-dispose to seizure
Any history of seizure or condition that may predispose to seizure
Patients with uncontrolled seizure disorders
No uncontrolled seizure disorders
Patients must not have a history of any type of seizure for at least 10 years prior to registration.
Concurrent treatment with medications known to have seizure potential
History of seizure or condition that may predispose to seizure
Patients must not have uncontrolled central nervous system disease; patients with a history of seizure disorders must be seizure-free for one year prior to enrollment
Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis
History of seizure or any condition that may predispose to seizure.
Seizure disorders requiring anticonvulsant therapy
History of seizure disorders
Any history of brain metastases or prior seizure or conditions predisposing to seizure activity
Focal or generalized seizure within the last 12 months.
Uncontrolled seizure activity.
History of seizure
Prior seizures < 3 months prior to enrollment. Subjects with a history of seizure disorders ? 3 months prior to enrollment must be seizure free and on stable anticonvulsant medication(s) for ? 3 months prior to enrollment).
Subjects with uncontrolled seizure
Seizure disorders
History of a seizure disorder diagnosis or have experienced a seizure in the past 12 months
PATIENTS: History of neuroleptic malignant syndrome or active seizure disorder (with seizure episode within the past week)
Patient has an active seizure disorder; (patients with a previous history of seizure disorders will be eligible for the study, if they have had no evidence of seizure activity, and they have been free of anti-seizure medication for the previous 5 years)
Survivors who report ever being diagnosed with a seizure disorder or have experienced a seizure in the past 12 months will be excluded
Patients who have a history of head injury or who have known seizure activity
Patients with seizure disorders treated with anticonvulsants
Patients who have a history of head injury or who have known seizure activity.
Any history of brain metastases or prior seizure or conditions predisposing to seizure activity
Documentation of history of seizure within previous 5 years
Patients with prior seizure history who have experienced a seizure within the three months prior to enrollment are excluded
Patients receiving glucocorticoids and/or anti-seizure medications are eligible for this study
Patients with a seizure history will not be permitted on protocol; patients on anticonvulsant medications will not be permitted on study
History of seizure or any condition that may predispose to seizure including, but not limited to, underlying brain injury, stroke in the past 6 months, primary brain tumors, brain metastases
Subject has a history of seizure or any condition that may predispose to seizure including, but not limited to, underlying brain injury, stroke in the past 6 months, primary brain tumors, brain metastases, prior seizures
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past; also, history of loss of consciousness or transient ischemic attack within 12 months of day 1 visit
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past; also, history of loss of consciousness or transient ischemic attack within 12 months before day 1
seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma).
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma)
Patient has a history of seizures or any condition that may predispose to seizures (e.g., prior cortical stroke, significant brain trauma) at any time in the past and/or a history of loss of consciousness or transient ischemic attack within 12 months of the cycle 1, day 1 visit.
History of seizure or any condition that may predispose subject to seizure (e.g., prior cortical stroke or significant brain trauma).
The subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma).
Subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma, encephalopathy within 3 months of Day 1).
seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma).
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, history of loss of consciousness or transient ischemic attack within 12 months of study entry); diabetics on a stable dose of insulin or antihyperglycemic regimen are allow if they have had no prior seizures and no history of loss of consciousness due to hypoglycemia
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past; also, history of loss of consciousness or transient ischemic attack within 12 months of day 1 visit
No history of seizure or any condition that may increase the patientâ€™s seizure risk (e.g., prior cortical stroke, significant brain trauma); no history of transient ischemic attack (TIA) within 12 months of enrollment
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, history of loss of consciousness or transient ischemic attack within 12 months of study entry) or concurrent medication that may predispose to seizure; diabetics on a stable dose of insulin or antihyperglycemic regimen are allowed if they have had no prior seizures and no history of loss of consciousness due to hypoglycemia
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma); also, history of loss of consciousness or transient ischemic attack within 12 months of enrollment
History of seizure or any condition that may predispose to seizures (e.g., prior cortical stroke or significant brain trauma) at any time in the past. History of loss of consciousness or transient ischemic attack within 12 months of screening.
History of (a) seizure or any condition that may predispose to seizure (prior cortical stroke or significant brain trauma); (b) loss of consciousness or transient ischemic attack within 12 months prior to day 1 of cycle 1.
History of seizure or any condition that may predispose subject to seizure (e.g., prior cortical stroke or significant brain trauma). History of loss of consciousness or transient ischemic attack within 12 months of randomization
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past; also, history of loss of consciousness or transient ischemic attack within 12 months of day 1 visit
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past; also, history of loss of consciousness or transient ischemic attack within 12 months of the day 1 visit
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, prior head or traumatic brain injury with loss of consciousness, prior or current space-occupying lesion in the brain); also, history of loss of consciousness or transient ischemic attack within 12 months of day 1 visit
Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke or transient ischemic attack within 1 year prior to first dose, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect); loss of consciousness within 12 months may be permitted upon discussion with study principle investigator (PI)
Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1year to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)
History of seizure or condition that may predispose to seizure; also, history of loss of consciousness or transient ischemic attack within 12 months of (day 1 visit)
Patients with history of seizure as an adult including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization). Also current or prior treatment with anti-epileptic medications for the treatment of seizures. Transient ischemic attack within 12 months prior to study enrollment will not be permitted.
History of seizure, seizure disorder, or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumors, brain metastases, or alcoholism. Also, history of loss of consciousness or transient ischemic attack within 12 months of enrollment (day 1 visit). Drugs may not be used which are known to decrease the seizure threshold
History of seizure or any condition that may increase the patientâ€™s seizure risk. Also, history of loss of consciousness or transient ischemic attack within 12 months of day 1
History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, prior head or traumatic brain injury with loss of consciousness, prior or current space-occupying lesion in the brain); also, history of loss of consciousness or transient ischemic attack within 6 months of enrollment
Patients with a history of seizure disorder, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, brain arteriovenous malformation
Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year to randomization, brain arteriovenous malformation, schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)
History of seizure or condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
History of any of the following:\r\n* Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)\r\n* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization\r\n* Any condition that in the opinion of the investigator, would preclude participation in this study
History of seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke or, loss of consciousness within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
History of seizure or any condition that may predispose to seizure; history of loss of consciousness or transient ischemic attack within 12 months before day 1
Patients with prior history of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain arteriovenous malformation or the use of concomitant medications that may lower the seizure threshold or other conditions predisposing to seizure
History of seizure or any condition that may predispose to seizure; history of loss of consciousness or transient ischemic attack within 12 months before day 1.
History of seizure or condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system (CNS) or meningeal disease which may require treatment with surgery or radiation therapy
History of seizure or any condition that may predispose to seizure within 12 months prior to study treatment, including history of unexplained loss of consciousness or transient ischemic attack
Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
Patients with a history of seizures, predisposing factors for seizures, including underlying brain injury with loss of consciousness within previous 12 months, transient ischemic attack within previous 12 months, cerebral vascular accident or brain arteriovenous malformation
History of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, and brain arteriovenous malformations
Patients with a history of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, brain arteriovenous malformation or the use of concomitant medications that may lower the seizure threshold
History of seizure including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization); also, current or prior treatment with antiepileptic medications for the treatment of seizures or history of loss of consciousness or transient ischemic attack within 12 months prior to randomization
History of seizure or condition that may predispose to seizure (e.g., prior stroke within 1 year of starting study drug, brain arteriovenous malformation)
History of seizures (taking/not taking anticonvulsants), arteriovenous malformation in the brain, head trauma with loss of consciousness
History of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumors, brain metastases, or alcoholism; also, history of loss of consciousness or transient ischemic attack within 12 months of enrollment (day 1 visit)
History of seizure, including any febrile seizure, loss of consciousness, or transient ischemic attack, or any condition that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization)
Patients with history of seizure as an adult including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization); also, current or prior treatment with anti-epileptic medications for the treatment of seizures or history of loss of consciousness; also transient ischemic attack within 12 months prior to randomization will not be permitted
Any history of seizure or a condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy).
Patients with predisposing factors for seizure including history of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastasis, and brain arteriovenous malformation
History of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain arteriovenous malformation or the use of concomitant medications that may lower the seizure threshold (not applicable to patients who have already been treated with enzalutamide in first line before inclusion).
History of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumors, brain metastases, or alcoholism. Also, history of loss of consciousness or transient ischemic attack within 12 months of enrollment (Day 1 visit)
History of seizure or any condition or concurrent medication that may predispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within one year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
History of significant neurological disease including poorly controlled seizures (i.e., > 1 seizure per month; anti-epileptic medications are acceptable), stroke, or head injury with loss of consciousness
Significant history of head injury/trauma as defined by loss of consciousness for more than one hour
Have a history of seizure or loss of consciousness
History of seizure including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization); also, current or prior treatment with antiepileptic medications for the treatment of seizures or history of loss of consciousness or transient ischemic attack within 12 months of enrollment
History of seizure, including any febrile seizure, loss of consciousness, or transient ischemic attack, or any condition that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization)
History of neurological disease known to affect cognition prior to initiating chemotherapy (e.g., stroke, head injury with loss of consciousness of > 30 minutes, seizure disorder, demyelinating disorder, mental retardation, primary brain tumor, brain metastases, etc.)
History of seizure, including any febrile seizure, loss of consciousness, or transient ischemic attack, or any condition that may predispose to seizure (e.g. prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization)
